Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.

Visentin A, Facco M, Gurrieri C, Pagnin E, Martini V, Imbergamo S, Frezzato F, Trimarco V, Severin F, Raggi F, Scomazzon E, Pravato S, Piazza F, Semenzato G, Trentin L.

Clin Lymphoma Myeloma Leuk. 2019 Mar 11. pii: S2152-2650(18)31763-4. doi: 10.1016/j.clml.2019.03.002. [Epub ahead of print]

PMID:
31371221
2.

A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia.

Visentin A, Deodato M, Mauro FR, Autore F, Reda G, Vitale C, Molica S, Rigolin GM, Piazza F, Cesini L, Tedeschi A, Laurenti L, Cassin R, Coscia M, Cuneo A, Foà R, Semenzato G, Trentin L.

Hematol Oncol. 2019 Jul 23. doi: 10.1002/hon.2655. [Epub ahead of print] No abstract available.

PMID:
31335982
3.

Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12.

Autore F, Strati P, Innocenti I, Corrente F, Trentin L, Cortelezzi A, Visco C, Coscia M, Cuneo A, Gozzetti A, Mauro FR, Frustaci AM, Gentile M, Morabito F, Molica S, Falcucci P, D'Arena G, Murru R, Vincelli D, Efremov DG, Ferretti A, Rigolin GM, Vitale C, Tisi MC, Reda G, Visentin A, Sica S, Foà R, Ferrajoli A, Laurenti L.

Cancers (Basel). 2019 Jun 26;11(7). pii: E896. doi: 10.3390/cancers11070896.

4.

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.

Visentin A, Bonaldi L, Rigolin GM, Mauro FR, Martines A, Frezzato F, Imbergamo S, Scomazzon E, Pravato S, Bardi MA, Cavallari M, Volta E, Cavazzini F, Nanni M, Del Giudice I, Facco M, Guarini A, Semenzato G, Foà R, Cuneo A, Trentin L.

Br J Cancer. 2019 Jul;121(2):150-156. doi: 10.1038/s41416-019-0502-x. Epub 2019 Jun 18.

PMID:
31209327
5.

HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia.

Frezzato F, Raggi F, Martini V, Severin F, Trimarco V, Visentin A, Scomazzon E, Accordi B, Bresolin S, Piazza F, Facco M, Basso G, Semenzato G, Trentin L.

Int J Cancer. 2019 Dec 1;145(11):3089-3100. doi: 10.1002/ijc.32383. Epub 2019 May 15.

PMID:
31044428
6.

Correlation Between Sleep-Time Masseter Muscle Activity and Tooth Wear: An Electromyographic Study.

Manfredini D, Lombardo L, Visentin A, Arreghini A, Siciliani G.

J Oral Facial Pain Headache. 2019 Spring;33(2):199-204. doi: 10.11607/ofph.2081.

PMID:
31013339
7.

p66Shc deficiency in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.

Patrussi L, Capitani N, Ulivieri C, Manganaro N, Granai M, Cattaneo F, Kabanova A, Mundo L, Gobessi S, Frezzato F, Visentin A, Finetti F, Pelicci PG, D'Elios MM, Trentin L, Semenzato G, Leoncini L, Efremov DG, Baldari CT.

Haematologica. 2019 Oct;104(10):2040-2052. doi: 10.3324/haematol.2018.209981. Epub 2019 Feb 28.

8.

Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients.

Riva M, Lessi F, Berno T, Visentin A, Campagnolo M, Semenzato G, Adami F, Briani C.

Leuk Lymphoma. 2019 Aug;60(8):2067-2070. doi: 10.1080/10428194.2018.1564048. Epub 2019 Jan 22. No abstract available.

PMID:
30668203
9.

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K; ERIC, the European Research Initiative on CLL.

Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan 2.

10.

Peripheral nervous system involvement in lymphomas.

Briani C, Visentin A, Campagnolo M, Salvalaggio A, Ferrari S, Cavallaro T, Manara R, Gasparotti R, Piazza F.

J Peripher Nerv Syst. 2019 Mar;24(1):5-18. doi: 10.1111/jns.12295. Epub 2019 Jan 8. Review.

PMID:
30556258
11.

Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.

Pizzi M, Trentin L, Visentin A, Saraggi D, Martini V, Guzzardo V, Righi S, Frezzato F, Piazza F, Sabattini E, Semenzato G, Rugge M.

Hum Pathol. 2019 Mar;85:251-259. doi: 10.1016/j.humpath.2018.10.038. Epub 2018 Nov 17.

PMID:
30458196
12.

Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL.

Pagano MA, Tibaldi E, Molino P, Frezzato F, Trimarco V, Facco M, Zagotto G, Ribaudo G, Leanza L, Peruzzo R, Szabò I, Visentin A, Frasson M, Semenzato G, Trentin L, Brunati AM.

Leukemia. 2019 May;33(5):1148-1160. doi: 10.1038/s41375-018-0288-5. Epub 2018 Oct 23.

PMID:
30353029
13.

Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.

Briani C, Visentin A, Salvalaggio A, Cacciavillani M, Trentin L.

Eur J Neurol. 2019 Feb;26(2):371-375. doi: 10.1111/ene.13838. Epub 2018 Nov 27.

PMID:
30315672
14.

Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia.

Martini V, Frezzato F, Severin F, Raggi F, Trimarco V, Martinello L, Molfetta R, Visentin A, Facco M, Semenzato G, Paolini R, Trentin L.

Oncotarget. 2018 Aug 14;9(63):32219-32231. doi: 10.18632/oncotarget.25951. eCollection 2018 Aug 14.

15.

Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases.

Visentin A, Campello E, Scomazzon E, Spiezia L, Imbergamo S, Pravato S, Piazza F, Semenzato G, Simioni P, Trentin L.

Hematol Oncol. 2018 Dec;36(5):801-803. doi: 10.1002/hon.2545. Epub 2018 Sep 6. No abstract available.

PMID:
30110712
16.

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.

Visentin A, Imbergamo S, Scomazzon E, Pravato S, Frezzato F, Bonaldi L, Pizzi M, Vio S, Gregianin M, Burei M, Facco M, Semenzato G, Piazza F, Trentin L.

Br J Haematol. 2019 Apr;185(1):193-197. doi: 10.1111/bjh.15440. Epub 2018 Jul 5. No abstract available.

PMID:
29974955
17.

Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.

Scapinello G, Pizzi M, Vio S, Nabergoj M, Visentin A, Martines A, Bonaldi L, Trentin L, Semenzato G, Piazza F.

Ann Hematol. 2018 Oct;97(10):2001-2003. doi: 10.1007/s00277-018-3351-4. Epub 2018 May 4. No abstract available.

PMID:
29728736
18.

In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.

Rigolin GM, Saccenti E, Guardalben E, Cavallari M, Formigaro L, Zagatti B, Visentin A, Mauro FR, Lista E, Bassi C, Lupini L, Quaglia FM, Urso A, Bardi MA, Bonaldi L, Volta E, Tammiso E, Ilari C, Cafforio L, Melandri A, Cavazzini F, Negrini M, Semenzato G, Trentin L, Foà R, Cuneo A.

Br J Haematol. 2018 Apr;181(2):229-233. doi: 10.1111/bjh.15174. Epub 2018 Apr 2.

PMID:
29611195
19.

The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma.

Canovas Nunes S, Manzoni M, Pizzi M, Mandato E, Carrino M, Quotti Tubi L, Zambello R, Adami F, Visentin A, Barilà G, Trentin L, Manni S, Neri A, Semenzato G, Piazza F.

Blood Cancer J. 2018 Feb 13;8(2):20. doi: 10.1038/s41408-018-0053-z.

20.

Palliative therapy in adults with cancer: a cross-sectional study.

Visentin A, Mantovani MF, Kalinke LP, Boller S, Sarquis LMM.

Rev Bras Enferm. 2018 Mar-Apr;71(2):252-258. doi: 10.1590/0034-7167-2016-0563. English, Portuguese.

21.

Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.

Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R.

Ann Oncol. 2018 Apr 1;29(4):966-972. doi: 10.1093/annonc/mdy021.

22.

p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes.

Patrussi L, Capitani N, Cattaneo F, Manganaro N, Gamberucci A, Frezzato F, Martini V, Visentin A, Pelicci PG, D'Elios MM, Trentin L, Semenzato G, Baldari CT.

Oncogene. 2018 Mar;37(11):1534-1550. doi: 10.1038/s41388-017-0066-2. Epub 2018 Jan 12.

PMID:
29326436
23.

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases.

Visentin A, Imbergamo S, Frezzato F, Pizzi M, Bertorelle R, Scomazzon E, Berno T, Riva M, Piva E, Facco M, Piazza F, Semenzato G, Trentin L.

Oncotarget. 2017 Sep 28;8(66):110727-110731. doi: 10.18632/oncotarget.21304. eCollection 2017 Dec 15.

24.

Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.

Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R.

Am J Hematol. 2018 Jan;93(1):58-64. doi: 10.1002/ajh.24935. Epub 2017 Nov 9.

25.

Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia.

Visentin A, Briani C, Imbergamo S, Frezzato F, Angelini A, Fedrigo M, Cacciavillani M, Altinier S, Piazza F, Semenzato G, Adami F, Trentin L.

Hematol Oncol. 2018 Feb;36(1):366-369. doi: 10.1002/hon.2480. Epub 2017 Oct 3.

PMID:
28971495
26.

Anti-sulfatide/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies.

Boso F, Ruggero S, Giannotta C, Benedetti L, Marfia GA, Ermani M, Campagnolo M, Salvalaggio A, Gallia F, De Michelis C, Visentin A, Bianco M, Ruiz M, Mataluni G, Nobile-Orazio E, Briani C.

Eur J Neurol. 2017 Nov;24(11):1334-1340. doi: 10.1111/ene.13387. Epub 2017 Aug 7.

PMID:
28782863
27.

Aberrant expression of CD10 and BCL6 in mantle cell lymphoma.

Pizzi M, Agostinelli C, Righi S, Gazzola A, Mannu C, Galuppini F, Fassan M, Visentin A, Piazza F, Semenzato GC, Rugge M, Sabattini E.

Histopathology. 2017 Nov;71(5):769-777. doi: 10.1111/his.13286. Epub 2017 Aug 8.

PMID:
28628241
28.

Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells.

Tibaldi E, Pagano MA, Frezzato F, Trimarco V, Facco M, Zagotto G, Ribaudo G, Pavan V, Bordin L, Visentin A, Zonta F, Semenzato G, Brunati AM, Trentin L.

Haematologica. 2017 Aug;102(8):1401-1412. doi: 10.3324/haematol.2016.155747. Epub 2017 Jun 15.

29.

CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.

Mandato E, Nunes SC, Zaffino F, Casellato A, Macaccaro P, Tubi LQ, Visentin A, Trentin L, Semenzato G, Piazza F.

Curr Cancer Drug Targets. 2018;18(6):608-616. doi: 10.2174/1568009617666170427110450.

PMID:
28460620
30.

Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.

Martini V, Gattazzo C, Frezzato F, Trimarco V, Pizzi M, Chiodin G, Severin F, Scomazzon E, Guzzardo V, Saraggi D, Raggi F, Martinello L, Facco M, Visentin A, Piazza F, Brunati AM, Semenzato G, Trentin L.

Br J Haematol. 2017 Jul;178(1):81-93. doi: 10.1111/bjh.14642. Epub 2017 Apr 17.

PMID:
28419476
31.

Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo.

Leanza L, Romio M, Becker KA, Azzolini M, Trentin L, Managò A, Venturini E, Zaccagnino A, Mattarei A, Carraretto L, Urbani A, Kadow S, Biasutto L, Martini V, Severin F, Peruzzo R, Trimarco V, Egberts JH, Hauser C, Visentin A, Semenzato G, Kalthoff H, Zoratti M, Gulbins E, Paradisi C, Szabo I.

Cancer Cell. 2017 Apr 10;31(4):516-531.e10. doi: 10.1016/j.ccell.2017.03.003.

32.

Role of miR-15a/miR-16-1 and the TP53 axis in regulating telomerase expression in chronic lymphocytic leukemia.

Rampazzo E, Bojnik E, Trentin L, Bonaldi L, Del Bianco P, Frezzato F, Visentin A, Facco M, Semenzato G, De Rossi A.

Haematologica. 2017 Jul;102(7):e253-e256. doi: 10.3324/haematol.2016.157669. Epub 2017 Apr 6. No abstract available.

33.

Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients.

Visentin A, Imbergamo S, Gurrieri C, Frezzato F, Trimarco V, Martini V, Severin F, Raggi F, Scomazzon E, Facco M, Piazza F, Semenzato G, Trentin L.

Eur J Cancer. 2017 Feb;72:103-111. doi: 10.1016/j.ejca.2016.11.020. Epub 2016 Dec 24.

PMID:
28027513
34.

Nerve ultrasound abnormalities mirror the course of varicella zoster virus sensory-motor radiculoplexopathy.

Salvalaggio A, Cacciavillani M, Visentin A, Campagnolo M, Trentin L, Briani C.

Muscle Nerve. 2017 Apr;55(4):E16-E18. doi: 10.1002/mus.25494. Epub 2016 Dec 28. No abstract available.

PMID:
27935069
35.

Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients.

Briani C, Visentin A, Salvalaggio A, Imbergamo S, Piazza F, Cacciavillani M, Campagnolo M, Frezzato F, Semenzato G, Trentin L.

Haematologica. 2017 Apr;102(4):e140-e143. doi: 10.3324/haematol.2016.153064. Epub 2016 Dec 7. No abstract available.

36.

The Nonmydriatic Fundus Camera in Diabetic Retinopathy Screening: A Cost-Effective Study with Evaluation for Future Large-Scale Application.

Scarpa G, Urban F, Vujosevic S, Tessarin M, Gallo G, Visentin A, Foglia E, Ferrario L, Midena E.

J Ophthalmol. 2016;2016:4625096. Epub 2016 Nov 3.

37.

Profiling B cell chronic lymphocytic leukemia by reverse phase protein array: Focus on apoptotic proteins.

Frezzato F, Accordi B, Trimarco V, Gattazzo C, Martini V, Milani G, Bresolin S, Severin F, Visentin A, Basso G, Semenzato G, Trentin L.

J Leukoc Biol. 2016 Nov;100(5):1061-1070. Epub 2016 Jun 16.

PMID:
27312846
38.

Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia.

Briani C, Visentin A, Cavallaro T, Cacciavillani M, Cabrini I, Ferrari S, Zambello R, Trentin L.

Ann Hematol. 2017 Jan;96(1):159-161. doi: 10.1007/s00277-016-2852-2. Epub 2016 Oct 19. No abstract available.

PMID:
27761605
39.

Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia.

Visentin A, Gurrieri C, Imbergamo S, Lessi F, Di Maggio SA, Frezzato F, Adami F, Zambello R, Piazza F, Semenzato G, Trentin L.

Hematol Oncol. 2017 Dec;35(4):925-928. doi: 10.1002/hon.2343. Epub 2016 Sep 19. No abstract available.

PMID:
27641225
40.

Assessment of Anxiety and Coping Features in Bruxers: A Portable Electromyographic and Electrocardiographic Study.

Manfredini D, Arreghini A, Lombardo L, Visentin A, Cerea S, Castroflorio T, Siciliani G.

J Oral Facial Pain Headache. Summer 2016;30(3):249-54. doi: 10.11607/ofph.1616.

PMID:
27472528
41.

Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.

Mondello P, Steiner N, Willenbacher W, Wasle I, Zaja F, Zambello R, Visentin A, Mauro E, Ferrero S, Ghione P, Pitini V, Cuzzocrea S, Mian M.

Ann Hematol. 2016 Jun;95(7):1107-14. doi: 10.1007/s00277-016-2668-0. Epub 2016 Apr 22.

PMID:
27103007
42.

Assessment of the risk of pressure ulcer development among hospitalized HIV/Aids patients.

Cidral S, Silva WF, Visentin A, Borghi AC, Mantovani Mde F, Hey AP.

Rev Bras Enferm. 2016 Jan-Feb;69(1):86-91. doi: 10.1590/0034-7167.2016690113i.

43.

Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival.

Trimarco V, Ave E, Facco M, Chiodin G, Frezzato F, Martini V, Gattazzo C, Lessi F, Giorgi CA, Visentin A, Castelli M, Severin F, Zambello R, Piazza F, Semenzato G, Trentin L.

Oncotarget. 2015 Dec 8;6(39):42130-49. doi: 10.18632/oncotarget.6239.

44.

Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy.

Visentin A, Compagno N, Cinetto F, Imbergamo S, Zambello R, Piazza F, Semenzato G, Trentin L, Agostini C.

Haematologica. 2015 Dec;100(12):e515-8. doi: 10.3324/haematol.2015.126763. Epub 2015 Aug 20. No abstract available.

45.

Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia.

Visentin A, Facco M, Frezzato F, Castelli M, Trimarco V, Martini V, Gattazzo C, Severin F, Chiodin G, Martines A, Bonaldi L, Gianesello I, Pagnin E, Boscaro E, Piazza F, Zambello R, Semenzato G, Trentin L.

Clin Lymphoma Myeloma Leuk. 2015 Oct;15(10):612-20.e1-5. doi: 10.1016/j.clml.2015.06.001. Epub 2015 Jun 20.

PMID:
26233718
46.

Analysis and improvement of organizational models for the management of patients with type 2 diabetes mellitus: a case study in north-east Italy.

Paccagnella A, Boaretto M, Confortin L, Sambataro M, Mauri A, Marcon ML, Cavasin F, Chinellato A, Faronato PP, Tessarin M, Spinella N, Visentin A, Pizzolato D, Santelli G.

Qual Manag Health Care. 2014 Apr-Jun;23(2):99-118. doi: 10.1097/QMH.0000000000000025.

PMID:
24710186
47.

Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole.

Frezzato F, Trimarco V, Martini V, Gattazzo C, Ave E, Visentin A, Cabrelle A, Olivieri V, Zambello R, Facco M, Zonta F, Cristiani A, Brunati AM, Moro S, Semenzato G, Trentin L.

Br J Haematol. 2014 Jun;165(5):659-72. doi: 10.1111/bjh.12815. Epub 2014 Mar 7.

PMID:
24606526
48.

Poly(ethylene glycol) diacrylate-supported ionogels with consistent capacitive behavior and tunable elastic response.

Visentin AF, Panzer MJ.

ACS Appl Mater Interfaces. 2012 Jun 27;4(6):2836-9. doi: 10.1021/am300372n. Epub 2012 May 16.

PMID:
22583832
49.

Open reduction and internal fixation of radial head fractures.

Iacobellis C, Visentin A, Aldegheri R.

Musculoskelet Surg. 2012 May;96 Suppl 1:S81-6. doi: 10.1007/s12306-012-0186-3. Epub 2012 Mar 25.

PMID:
22447441
50.

Personal exposure to particulate matter is associated with worse health perception in adult asthma.

Maestrelli P, Canova C, Scapellato ML, Visentin A, Tessari R, Bartolucci GB, Simonato L, Lotti M.

J Investig Allergol Clin Immunol. 2011;21(2):120-8.

Supplemental Content

Loading ...
Support Center